52 results about "Circadian Rhythm Disorders" patented technology

This invention provides methods of administering (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclo-propyl]methyl]propanamide as a melatonin receptor agonist to a human subject to treat or prevent a circadian rhythm disorder or sleep disorder.

The present invention provides a circadian rhythm normalizing composition containing astaxanthin and / or its ester as an active ingredient, and a composition having the action of enhancing the circadian rhythm normalizing action of melatonin by protecting melatonin. The composition can be in the form of a drug, a functional food, a food or a beverage.This composition has a circadian rhythm normalizing action, and has the action of preventing or alleviating sleep disorder and various diseases due to disturbance of the circadian rhythm.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

A novel pyrazole derivative of the following formula having a histamine H3 receptor antagonistic effect:or a pharmaceutically acceptable salt thereof or a pharmaceutical preparation comprising the same as an active ingredient is effective for prevention or treatment of dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases.

Methods to prepare a bio-replenishment (BioRep) with specific combinations of S-adenosylmethionine (SAMe), lactoferrin (LF) and ribonuclease (RNAse) to restore regular sleep pattern are described. Additionally, compositions of functional delivery systems that recreate both alternate phases of non-rapid eye movement (NREM) and rapid eye movement (REM) sleep cycles are disclosed. These methods and compositions have implications in the clinical management of various sleep disorders including insomnia, circadian rhythm disorders and obstructive sleep apnea.

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

Apparatus and methods for treating psychiatric disorders, mood disorders and circadian rhythm disorders with a multi-stage light protocol are disclosed. The presently disclosed multi-stage light protocol provides a synergistic treatment including up to 4 types of therapies: bright light therapy, extended sleep deprivation therapy, dawn simulation therapy and short to medium wavelength light therapy. According to some embodiments, the first stage of the protocol includes a first time window of 20 minutes during which, for a majority of the time, the light intensity is between 50 lux and 2000 lux. According to some embodiments, the second stage of the protocol includes a second time window of at least 90 minutes during which, for every 10 minute period within the second time window, for a majority of the time, the light intensity is exceeds 100 lux. According to some embodiments, the third stage of the protocol includes a third time window of 60 minutes during which, for a majority of the time, the light intensity exceeds 2000 lux In some embodiments, the light is provided by apparatus including a plurality of LEDs. Typically, the light includes white light having a broad spectrum. In some embodiments, the light further includes light having a medium wavelength, for example, wavelengths between 520 nm and 535 nm.

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnnia, repetitive hypersomnnia, true hypersomnnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

The invention discloses a circadian rhythm disorder therapeutic instrument. The therapeutic instrument comprises a spectacle type model frame, a patch light-emitting diode module, a power supply and a light guide plate assembled in the spectacle type model frame, wherein the light guide plate is positioned below a light emitting surface of the patch light-emitting diode module to uniformly scatter light output by a light-emitting diode and weaken axial light intensity. The invention also discloses a method for manufacturing the circadian rhythm disorder therapeutic instrument. The axial light intensity of the patch light-emitting diode is weakened by a light guide plate technique, so the safety of retina in irradiation therapy is ensured and the device has the advantages of convenience and safety.

The invention provides a method for screening for a compound for modulating circadian rhythm. The method involves (a) providing a compound that is a Prokineticin 2 (PK2) receptor antagonist or agonist; and (b) determining the ability of the compound to modulate one or more indicia of circadian rhythm function, wherein a compound that modulates one or more indicia of circadian rhythm function is identified as a compound for modulating circadian rhythm. The invention also provides a mouse PK2 receptor nucleic acid, polypeptide and related compositions. Further provided is a method for modulating circadian rhythm of an animal, which involves administering an effective amount of a PK2 receptor antagonist or agonist to an animal. Also provided is an isolated nucleic acid comprising a PK2 gene promoter operatively linked to a heterologous nucleotide sequence.

A portable, lightweight, head-mounted light therapy device is disclosed. The device comprises one or more selectable light sources, such as light emitting diodes (LEDs), to provide bright or dim red light, bright or dim white light, or a combination thereof, selectable by the user, for shining on the user's face and eyes. The device can be used for the treatment of light deficiency disorders or conditions and circadian rhythm disorders and disturbances.

The invention discloses a construction method of a non-alcoholic fatty liver mouse model. According to the method, construction of a mouse non-alcoholic fatty liver model is induced by cooperation ofhigh-fat and high-sugar diet and circadian rhythm disorder. The method is short in consumed time, high in modeling success rate, low in cost and free of toxic and side effects caused by use of chemical reagents, and is called as a green animal model.

The present invention relates to a composition for regulating circadian rhythms, a composition for diagnosing circadian rhythm disorders and a diagnostic kit, wherein the composition for regulating circadian rhythms comprises NQ peptides, C12orf39 genes, NQ peptides cDNA and the like, which relate to circadian regulation in vertebrates as main components.

The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases.A phenylpyrazole derivative represented by formula (1) or a pharmaceutically acceptable salt thereof:{whereinR1 and R2, which may be the same or different, each represent C1-C6 alkyl or C3-C8 cycloalkyl, orR1 and R2 are attached to each other together with their adjacent nitrogen atom to form a 4- to 7-membered saturated heterocyclic ring (wherein said saturated heterocyclic ring may be substituted with halogen or C1-C6 alkyl),n represents an integer of 0 to 2,T represents a hydrogen atom, halogen or C1-C6 alkyl, andR represents formula (I):or the like}.

Provided are novel compounds that are useful in the prevention or treatment of such diseases as dementia, Alzheimer's disease, attention-deficient hyperactivity disorder, schizophrenia, epilepsy, central convulsion, obesity, diabetes mellitus, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behaviorally induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm disorder, parasomnia, sleep related movement disorder, insomnia, and depression, or allergic rhinitis, or pharmaceutically acceptable salts of such compounds. Specifically, there are provided phenylpyrrole compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof:Formula (I)[wherein Q refers to a group represented by the following formula (A) or (B):

A method for controlling circadian rhythm disorders is described, characterized by inhibiting the phosphorylation of BMAL1 by c-Jun N-terminal kinase 3 (JNK3) due to the interaction between JNK3 and BMAL1; a method for preventing and / or treating diseases caused by circadian rhythm disorders; and a method for identifying a compound that inhibit phosphorylation of BMAL1 by JNK3. Also provided are: an agent for controlling circadian rhythm disorders, having the above characteristics; an agent for treating and / or preventing diseases caused by circadian rhythm disorders; a compound obtained by the identification method described above; an agent for inhibiting the phosphorylation of BMAL1 by JNK3, containing the compound; an agent for recovering the suppressed transcriptional activity of the complexes containing BMAL1 and CLOCK and for inhibiting the phosphorylation the same, containing an agent for inhibiting the expression and / or function of JNK3; and a pharmaceutical composition containing one of these.

The invention discloses application of an HMGB1 in serving as a biomarker for circadian rhythm sleep disorders. By detecting the level of the HMGB1 in a biological sample, circadian rhythm disorder and sleep disorder state is judged, and a reference is provided for judgement at the molecular level accordingly.

Solid state lighting devices with melatonin suppression characteristics that ameliorate or reduce symptoms of circadian rhythm disorders or other health conditions. Aspects disclosed herein additionally relate to providing one or more of the foregoing effects while maintaining color rendering index (CRI) values acceptably high for the intended use, as well as providing lighting devices with high luminous efficacy and enhanced energy efficiency. A solid state lighting device includes one or more solid state emitters and one or more lumiphoric materials that provide aggregated emissions of the solid state lighting device. The aggregated emissions have a warm correlated color temperature (CCT) with a color point that is off of the blackbody locus (BBL) by a certain distance.

The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases.A phenylpyrazole derivative represented by formula (1) or a pharmaceutically acceptable salt thereof:{whereinR1 and R2, which may be the same or different, each represent C1-C6 alkyl or C3-C8 cycloalkyl, orR1 and R2 are attached to each other together with their adjacent nitrogen atom to form a 4- to 7-membered saturated heterocyclic ring (wherein said saturated heterocyclic ring may be substituted with halogen or C1-C6 alkyl),n represents an integer of 0 to 2,T represents a hydrogen atom, halogen or C1-C6 alkyl, andR represents formula (I):or the like}.

Provided is a novel oxazolone derivative having an inhibitory activity on casein kinase 1[delta] and casein kinase 1[epsilon]. The inhibitor can inhibit casein kinase 1[delta] and casein kinase 1[epsilon], and therefore can provide a medicinal agent useful for the treatment and / or prevention of diseases of which the disease condition are associated with the mechanism of activation of casein kinase 1[delta] or casein kinase 1[epsilon]. Particularly, the inhibitor can provide a medicinal agent useful for the treatment of circadian rhythm disorders (including sleep disorder), central nervous system degenerative diseases and cancer. An inhibitor of casein kinase 1[delta] and casein kinase 1[epsilon], which comprises an oxazolone derivative represented by general formula (1), a salt of the derivative, or a solvate or hydrate of the derivative or the salt as an active ingredient. [In formula (1), X represents a halogen atom (which may be any one of a fluorine atom, a chlorine atom, a bromine atom and an iodine atom).]

There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1δ and casein kinase 1ε. In addition, the present inhibitor inhibits casein kinase 1δ and casein kinase 1ε, and thus there is also provided a pharmaceutical agent useful for the treatment and / or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1δ or casein kinase 1ε is associated. There is further provided a pharmaceutical agent useful for the treatment of particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer.An inhibitor of casein kinase 1δ and casein kinase 1ε comprising, as an act ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof:wherein X represents a halogen atom (which may be any one of a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom).

The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases.A dihydroquinolinone derivative represented by formula (1) or a pharmaceutically acceptable salt thereof:{wherein Q represents the following formula (A) or (B)}

The present invention relates to a composition used for preventing or reducing circadian rhythm disorders and comprising a Lespedeza plant extract as an active ingredient, wherein the composition enhances the biological clock rhythmicity, and can be usefully used as a composition capable of improving, preventing or treating skin damage caused by the biorhythm disorders through the action. In addition, the Lespedeza plant extract is a chemical substance derived from plants and is safe as the Lespedeza plant extract has little side effects on the human body, thereby being safely applied to cosmetics, pharmaceuticals and food compositions.

There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1δ and casein kinase 1ε. In addition, the present inhibitor inhibits casein kinase 1δ and casein kinase 1ε, and thus there is also provided a pharmaceutical agent useful for the treatment and / or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1δ or casein kinase 1ε is associated. There is further provided a pharmaceutical agent useful for the treatment of, particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer. An inhibitor of casein kinase 1δ and casein kinase 1ε comprising, as an active ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof:wherein X represents a halogen atom which is fluorine, chlorine, bromine or iodine.